Therefore, blockade of PGK1 or ALDOA should be considered as a potential immunotherapeutic strategy to boost AhR activation and ultimately control Th17 cell inflammatory potential while favoring the acquisition of suppressive features by these cells in Crohn’s disease. This evidence concerns the gene AHR and Crohn disease.